BCEL Description — Atreca Inc

Atreca is a clinical-stage biopharmaceutical company utilizing its platform to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101.

Company Name: 
Atreca Inc
Number of ETFs Holding BCEL: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   BCEL Weight   BCEL Amount 
 VTI   0.00%   $932,634         
 VXF   0.00%   $404,377         
 IWC   0.01%   $59,778         
 ITOT   0.00%   $49,444         
Quotes delayed 20 minutes

Email EnvelopeFree BCEL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
97th percentile
(ranked higher than approx. 97% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding BCEL | Atreca Inc | ETF Channel |

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.